Skip to main content
Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report.
Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.
A transgenic mouse model of Down syndrome acute lymphoblastic leukemia identifies targetable vulnerabilities.
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.
Down syndrome and leukemia: from basic mechanisms to clinical advances.
Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia.
Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia.
A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment.
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.